Clinical Research Directory
Browse clinical research sites, groups, and studies.
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Sponsor: Wenjin Yin
Summary
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Official title: Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
86
Start Date
2023-06-01
Completion Date
2027-02
Last Updated
2025-09-11
Healthy Volunteers
No
Conditions
Interventions
XC
Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
TPC
Any physician's choice as maintenance therapy (except for XC regimen)
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China